Chest
Original ResearchScoring System and Clinical Application of COPD Diagnostic Questionnaires
Section snippets
Materials and Methods
Details of the development of the questionnaires have been described elsewhere.10, 11 In brief, two study sites (Aberdeen, Scotland and Denver, CO) were chosen for the evaluation. Subjects ≥ 40 years old were randomly selected from primary care practice rosters in these sites and invited by mail to participate in the study. Eligible respondents were enrolled after providing informed consent. Respondents were eligible if they reported the following: (1) a positive smoking history (current or
Results
The ROC curves are presented for the case-finding (Fig 1) and differential diagnosis (Fig 2) questionnaires, along with selected performance characteristics (Table 3). For each ROC curve, two cut points were determined by assessing the performance characteristics of the questions to choose those points representing the optimal combination of PPV, NPV, and the distribution of subjects between cut points. This system places subjects within one of three zones, depending on their likelihood of
Discussion
Prior work10, 11 has demonstrated that questionnaires based on patient-reported information can be used to identify persons likely to have COPD among specific risk groups. This study adds a simple scoring system to make these instruments practical for use in the primary care setting. Using this scoring system, these instruments demonstrated ROC performance comparable to that of other respiratory screening questionnaires, as illustrated in Table 6. In COPD, for example, retrospective analyses
Conclusions
The questionnaires described here can be used to identify persons likely to have COPD among specific risk groups. This can be done with acceptable performance characteristics. The use of a simple scoring system makes these tools beneficial in the primary care setting. Used in conjunction with spirometry, these tools can help improve the efficiency and accuracy of COPD diagnosis in primary care. Future work should address the reliability of the instruments, validity in different populations and
Appendix
Members of the COPD Questionnaire Study Group include William Erhardt, MD, Pfizer Inc, New York, NY; Daryl Freeman, MD, University of Aberdeen, Aberdeen, Scotland; R. J. Halbert, MD, MPH, Cerner Health Insights, Beverly Hills, CA; Thomas Hausen, MD, Essen, Germany; Sharon Isonaka, MD, MS, Cerner Health Insights, Beverly Hills, CA; Elizabeth F. Juniper, MSc, McMaster University, Hamilton, ON, Canada; Claus Justus, DVM, Boehringer Ingelheim International GmbH, Ingelheim, Germany; Mark L. Levy,
ACKNOWLEDGMENT
The authors thank the subjects who participated in the study; the staff who collected the data; study coordinators Jan Caldow in Aberdeen and Melanie Gleason in Denver; Dr. John L. Adams, who provided statistical advice; and Dr. Michael Levine, who served as a spirometry reviewer.
References (20)
- et al.
Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program
Chest
(2000) - et al.
New international primary care airways guidelines (IPAG)
Revue Française d’Allergologie et d’Immunologie Clinique
(2003) - et al.
Early detection of COPD in a high-risk population using spirometric screening
Chest
(2001) Diagnosis of asthma and chronic obstructive pulmonary disease in general practice
Br J Gen Pract
(1996)National Lung Health Education Program. Strategies in preserving lung health and preventing COPD and associated diseases
Chest
(1998)Underdiagnosis of asthma and COPD: is the general practitioner to blame?
Monaldi Arch Chest Dis
(2002)- et al.
Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study
BMJ
(2002) - et al.
Development of a population-based screening questionnaire for COPD
J COPD
(2005) - et al.
Comparison of existing symptom-based questionnaires for identifying COPD in the general practice setting
Respirology
(2005)
Cited by (0)
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml)
for the COPD Questionnaire Study Group
Dr. Price has received honoraria for speaking at sponsored meetings and serving on advisory panels for the following companies marketing COPD products: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Pfizer. He or his research team have received funding for research projects from the same companies. Dr. Tinkelman is an employee of National Jewish Medical and Research Center, which received funding from Boehringer Ingelheim to participate in this study. At the time this work was performed, Drs. Nordyke, Isonaka and Halbert were employees of Cerner Health Insights, which provides consulting services to the pharmaceutical industry, including the sponsors of this project.
Portions of this article were presented at meetings of the International Primary Care Respiratory Group (International Congress: Melbourne, Australia; February 19 to 22, 2004) and the Asian Pacific Society of Respirology (Ninth Congress: Hong Kong, December 10 to 13, 2004).
This project was funded by Boehringer Ingelheim International GmbH and Pfizer Inc.